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Introduction
Here we are presenting a case of sarcoidosis with
extensive systemic and neurologic involvement.
Although different immunosuppressant modalities were
used, the neurological symptoms recurred. Management
of neurosarcoidosis can be challenging and needs multi-
disciplinary approach.
Objectives
Presenting a case of sarcoidosis with extensive systemic
and neurologic involvement.
Methods
A male patient, who was 14 years old at that time,
applied to the emergency department 4 years ago with
right sided hemiplegia, right sided hemianopsia and
disarticulated speech. Cranial MRI showed T2 and flair
hyperintensities on optic tractus and chiasma opticum.
This finding was consistent with either neoplastic diseases
or aggressive inflamatory processes. Lomber punction
revealed no specific finding. As the patient had pansitope-
nia, bone marrow aspiration / biopsy was performed.
Paratrabecular granuloma was found in the bone marrow
biopsy. To analyse pansitopenia and Hepatosplenomegaly,
the patient underwent portal Doppler USG imaging.
Splenic vein calibration seemed to be increased. A gastro-
scopy was performed and grade 1 esophagus varices were
visualized. Abdominal CT scan showed many lymph
nodes of 2 cm or larger. Hepatic biopsy showed non-
necrotizing granulomatous lesions and EZN stains were
negative. Abdominal lymph node biopsy was performed
by a laparotomy and Schaumann bodies were seen at the
microscopic analysis.
The patient was given 60 mg methylprednisolone
daily and 20 mg MTX weekly. MRI after 3 weeks
showed minimal regression and clinical signs of the
patient ameliorated. Steroid was continued by tapering
the dose and MTX was given for 6 months. As the
neurological signs of the patients couldn’t be cured,
patient was re-admitted after 6 months. MRI showed
prominent progression in the lesions. Spinal MRI
showed sequel lesions due to involvement of the spinal
cord. Infliximab treatment was planned but couldn’t be
continued as allergic reaction developed. Cyclopho-
sphamid treatment was started but had to be stopped
after 5 doses because of side effects (nausea, vomiting).
In order to manage the progressive neurologic findings
Rituximab (4 doses in total) was applied. However
patient presented with recurrent neurological findings
and Adalimumab treatment was given. Hepatic sarcoids
were regressed in abdominal USG but gastroscopic
images showed grade 2 esophagus varices. Patient had
received a total of 3 doses till now and seems to have a
slow regression for neurological findings.
Results
Adalimumab treatment can be effective for
neurosarcoidosis.
Conclusion
Management of neurosarcoidosis could be challenging
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